Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Medy-Tox received₩148 Mil more from issuing new shares than it paid to buy back shares.
It spent₩284 Mil paying down its debt.
It paid₩0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received₩0 Mil from paying cash dividends to shareholders.
It spent₩988 Mil on other financial activities.
In all, Medy-Toxspent₩1,124 Mil on financial activities for the
three
months ended in Mar. 2024.
Medy-Tox Cash Flow from Financing Historical Data
The historical data trend for Medy-Tox's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Medy-Tox's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,747 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medy-Tox (XKRX:086900) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Medy-Tox's issuance of stock for the
three
months ended in Mar. 2024 was ₩148 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Medy-Tox's repurchase of stock for the
three
months ended in Mar. 2024 was ₩0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Medy-Tox's net issuance of debt for the
three
months ended in Mar. 2024 was ₩-284 Mil.
Medy-Tox spent₩284 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Medy-Tox's net issuance of preferred for the
three
months ended in Mar. 2024 was ₩0 Mil.
Medy-Tox paid₩0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Medy-Tox's cash flow for dividends for the
three
months ended in Mar. 2024 was ₩0 Mil.
Medy-Tox received₩0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Medy-Tox's other financing for the
three
months ended in Mar. 2024 was ₩-988 Mil.
Medy-Tox spent₩988 Mil on other financial activities.
Medy-Tox Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Medy-Tox's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:086900 has been successfully added to your 